VSTM2L and gastric adenocarcinoma: In order to evaluate the prognostic value of VSTM2L in STAD and KIRP, we examined survival data from the Kaplan–Meier Plotter database in relation to clinicopathologic factors (Table 1) and immune cell profile (Table 2).